Non-Small Cell Lung Cancer (NSCLC)

Focusing on PD-L1-low NSCLC, Faith Abodunrin, MD, discusses the decision to rechallenge with immunotherapy.

Jyoti Patel, MD, presents the case of a patient with EGFR-mutated non–small cell lung cancer requiring treatment following osimertinib.

Initiating a conversation on patient cases, Divya Gupta, MD, presents the profile of a 76-year-old woman with ROS1+ metastatic non–small cell lung cancer.

Divya Gupta, MD, presents data from CHRYSALIS-2 focused on amivantamab plus lazertinib in atypical EGFR-mutated advanced non–small cell lung cancer.

Robert B. Cameron, MD, PhD, reviews data from the LAURA trial investigating osimertinib in patients with EGFR-mutated stage III unresectable NSCLC.

Focusing on the CROWN study, Faith Abodunrin, MD, discusses the role of lorlatinib in the treatment of patients with non–small cell lung cancer.

Laila Gharzai, MD, discusses findings from the BRIGHTSTAR trial which evaluated brigatinib in TKI-naïve patients with ALK-rearranged metastatic non–small cell lung cancer.

Joshua K. Sabari, MD, introduces a Face-Off program in which Northwestern University and the University of Chicago will present data and discuss treatment practices in non–small cell lung cancer.

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

The Oncology Brothers and Isabel Preeshagul, DO, MBS, share clinical insights on later-line treatment practices for patients with metastatic non–small cell lung cancer.

Isabel Preeshagul, DO, MBS, and the Oncology Brothers discuss the treatment of patients with NSCLC and actionable mutations following progression on first-line therapy.

Medical oncologists discuss the role of dual checkpoint inhibitors with chemotherapy in the treatment of patients with metastatic non–small cell lung cancer.

Isabel Preeshagul, DO, MBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for newly diagnosed patients with metastatic non–small cell lung cancer (NSCLC) and no actionable mutations.

As of data cutoff, 6 patients with NSCLC in the phase 2 THIO-101 trial are receiving ongoing treatment with THIO plus cemiplimab after 12 months.

Feedback from a Type C meeting signals the end of preparatory regulatory interactions for the phase 3 TACTI-004 trial’s design in metastatic NSCLC.

Preclinical data support the potential anti-tumor activity and tolerability of a novel FR⍺ topoisomerase I inhibitor in ovarian cancer and NSCLC.

Balazs Halmos, MD, and the Oncology Brothers discuss therapeutic practices for patients with NSCLC, highlighting how MET exon 14 skipping mutations and RET rearrangements inform treatment decisions.

The Oncology Brothers and Balazs Halmos, MD, provide clinical insights on therapeutic options for patients with NSCLC with rare mutations, including ROS1, BRAF V600E, and NTRK.

Medical oncologists discuss therapeutic practices for patients with non–small cell lung cancer with ALK mutations.

A thoracic medical oncologist provides insights on the treatment of patients with non–small cell lung cancer with uncommon EGFR mutations.

Balazs Halmos, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with non–small cell lung cancer (NSCLC) with common sensitizing EGFR mutations.

The conundrum of treating dermatologic adverse effects in response to treatment with amivantamab for EGFR-mutated NSCLC was discussed in a recent Frontline Forum.

The results of the trial showed that at least 75% of patients with NSCLC harboring driver gene alterations may benefit from this treatment.

Findings from the phase 3 FLAURA2 trial support the European approval of osimertinib/chemotherapy in EGFR-mutated non–small cell lung cancer.

Developers intend to halt the phase 2/3 SKYSCRAPER-06 trial assessing tiragolumab plus atezolizumab and chemotherapy in nonsquamous NSCLC.

The first-in-class tetravalent bispecific antibody may show binding affinity to PD1 and VEGF based on in vitro studies.

The complete response letter for patritumab deruxtecan is based on findings related to a third-party manufacturing site inspection.

The approval for osimertinib/chemotherapy by the Japanese Pharmaceuticals and Medical Device Agency was based on results from the phase 3 FLAURA2 trial.

Disease-free survival did not show statistical significance for patients with early-stage non–small cell lung cancer treated with durvalumab.

Misako Nagasaka, MD, PhD, discussed the approval of amivantamab plus chemotherapy for patients with EGFR exon 20 insertion mutations non–small cell lung cancer.